VTRS

ViatrisA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

Curated Events

Active

Recent Headlines

New

Curated events

Materiality

85.25

m&a

Source

External coverage

Decided

2026-10-09

Viatris makes foray into non-opioid pain space on $1.65bn Pacira buyout

Viatris agreed to acquire Pacira for $1.65 billion, expanding into non-opioid pain therapies. The deal is a positive strategic read-through for VTRS and offers a defined cash-acquisition catalyst for PCRX, subject to closing conditions.

View event details3 more curated

Sentiment decomposition

+30.0

30-day score

Company+30.055%

Macro-30%

Pulse-15%

Weekly research-10-day

Company, Macro, and Pulse form the existing 30-day artifact blend. Weekly research is tracked separately for 10 days and can contribute at most 10% of the sentiment pillar when live mode is enabled.

Top contributor

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

+0.30 sentiment - 2026-10-08

Recent headlines

No supplemental ticker headlines stored yet

We are still collecting relevant articles for VTRS. Curated events highlight the most material developments impacting this ticker right now.

Check curated events Open full news archive

As of 2026-10-08 • Updated scheduledSource: News desk